loading
Schlusskurs vom Vortag:
$26.13
Offen:
$25.98
24-Stunden-Volumen:
1.97M
Relative Volume:
0.48
Marktkapitalisierung:
$3.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-27.58
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-11.40%
1M Leistung:
-10.53%
6M Leistung:
-58.38%
1J Leistung:
-68.72%
1-Tages-Spanne:
Value
$25.21
$26.23
1-Wochen-Bereich:
Value
$25.21
$29.60
52-Wochen-Spanne:
Value
$24.44
$82.00

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Firmenname
Viking Therapeutics Inc
Name
Telefon
858-704-4660
Name
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Mitarbeiter
0
Name
Twitter
@viking_vktx
Name
Nächster Verdiensttermin
2024-10-23
Name
Neueste SEC-Einreichungen
Name
VKTX's Discussions on Twitter

Vergleichen Sie VKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VKTX
Viking Therapeutics Inc
25.65 3.29B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Eingeleitet Scotiabank Sector Outperform
2025-02-07 Eingeleitet Citigroup Neutral
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-11-22 Eingeleitet B. Riley Securities Buy
2024-11-04 Bestätigt H.C. Wainwright Buy
2024-09-11 Eingeleitet JP Morgan Overweight
2024-06-27 Eingeleitet Morgan Stanley Overweight
2024-05-16 Hochstufung Raymond James Outperform → Strong Buy
2024-03-26 Bestätigt Oppenheimer Outperform
2024-03-07 Eingeleitet Jefferies Buy
2024-02-28 Bestätigt Oppenheimer Outperform
2023-05-31 Fortgesetzt ROTH MKM Buy
2023-03-28 Bestätigt Maxim Group Buy
2023-03-17 Eingeleitet Stifel Buy
2021-07-29 Fortgesetzt BTIG Research Buy
2021-05-25 Herabstufung Raymond James Strong Buy → Outperform
2020-06-05 Eingeleitet BMO Capital Markets Outperform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-05-01 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-25 Eingeleitet Stifel Buy
2019-03-29 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-03-14 Bestätigt Maxim Group Buy
2019-02-22 Eingeleitet SVB Leerink Mkt Perform
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-11-19 Hochstufung Raymond James Outperform → Strong Buy
2018-09-18 Bestätigt H.C. Wainwright Buy
2018-09-18 Bestätigt Maxim Group Buy
2018-09-18 Bestätigt Raymond James Outperform
2018-07-20 Eingeleitet SunTrust Buy
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-01 Bestätigt Laidlaw Buy
2018-05-31 Bestätigt Maxim Group Buy
2018-03-26 Fortgesetzt H.C. Wainwright Buy
2017-11-28 Bestätigt Maxim Group Buy
2017-11-21 Eingeleitet ROTH Capital Buy
Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

pulisher
Mar 28, 2025

A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily

Mar 26, 2025
pulisher
Mar 26, 2025

Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online

Mar 26, 2025
pulisher
Mar 26, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - StockTitan

Mar 26, 2025
pulisher
Mar 25, 2025

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN

Mar 25, 2025
pulisher
Mar 24, 2025

Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

(VKTX) Investment Analysis - Stock Traders Daily

Mar 24, 2025
pulisher
Mar 21, 2025

Market Whales and Their Recent Bets on VKTX Options - Benzinga

Mar 21, 2025
pulisher
Mar 20, 2025

1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Yahoo

Mar 19, 2025
pulisher
Mar 18, 2025

Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool

Mar 18, 2025
pulisher
Mar 18, 2025

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat

Mar 18, 2025
pulisher
Mar 17, 2025

Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN

Mar 15, 2025
pulisher
Mar 14, 2025

Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN

Mar 14, 2025
pulisher
Mar 13, 2025

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 13, 2025

(VKTX) Long Term Investment Analysis - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research

Mar 13, 2025
pulisher
Mar 13, 2025

Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

10 Stocks Skyrocketing Today - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Why VKTX Stock is Moving Today - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch

Mar 12, 2025
pulisher
Mar 12, 2025

Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga

Mar 12, 2025
pulisher
Mar 12, 2025

B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics call volume above normal and directionally bullish - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Viking shares slip after manufacturing deal announced - The Pharma Letter

Mar 12, 2025
pulisher
Mar 12, 2025

VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart

Mar 11, 2025
pulisher
Mar 11, 2025

Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma

Mar 11, 2025
pulisher
Mar 11, 2025

Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com

Mar 11, 2025

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mancini Marianna
Chief Operating Officer
Jan 06 '25
Sale
42.75
54,215
2,317,599
374,134
ZANTE GREG
Chief Financial Officer
Jan 06 '25
Sale
42.75
50,309
2,150,595
165,259
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Kapitalisierung:     |  Volumen (24h):